Related Experiment Video
Updated: Jul 3, 2026

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
Short-term outcomes associated with surfactant use in respiratory distress in late preterm to early term infants
Catherine Peterson1,2, Kasim Hassen1, Susan Avila Misciagno2
1Neonatal Research Institute, Sharp Mary Birch Hospital for Women & Newborns, San Diego, CA, USA.
Objective:
Evaluate surfactant therapy and clinical outcomes including length of hospital stay (LOS), CPAP, and mechanical ventilation in late preterm to early term infants.
Study Design:
A single-center retrospective study of 401 eligible infants 33-38 + 6 weeks. Surfactant administration included INSURE (INtubation-SURfactant-Extubation), LISA (Less Invasive Surfactant Administration), and endotracheal with prolonged invasive ventilation.
Results:
114 (28%) received surfactant. Surfactant-treated infants had longer LOS (16 ± 11 vs 12 ± 9 days, p < 0.001) compared to non-treated. Infants who received INSURE/LISA (n = 43) had shorter LOS (14 ± 9 vs 18 ± 12 days, p = 0.04) than endotracheal surfactant with prolonged mechanical ventilation (n = 71). Infants who received INSURE/LISA had similar LOS to non-surfactant-treated infants (14 ± 9 vs 13 ± 9 days, p = 0.47).
Conclusion:
Surfactant administration was associated with longer hospitalization compared to non-treated infants. INSURE/LISA shortened LOS compared to surfactant with prolonged ventilation. In late preterm and early term infants that require surfactant for RDS, less invasive methods reduce LOS.
Related Concept Videos
Breathing
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Pulmonary Cycle: Exhalation
Respiratory Syncytial Virus Disease
Acute Respiratory Failure-IV
